Human IgG2 monoclonal antibody to cardiac troponin I, clone 5F8

Catalogue #

R1-126-100

Name

Human IgG2 monoclonal antibody to cardiac troponin I, clone 5F8

Description

The epitope for clone 5F8 corresponds to the following amino acid (aa) positions in the cTnI protein sequence: 40-55.

Target

Recombinant human cardiac troponin complex

Target Description

Recombinant human cardiac troponin complex protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line.

Alternative Names

CMD1FF, CMD2A, CMH7, RCM1, TNNC1

Uniprot ID

P19429

Clonality

Human monoclonal

Clone

5F8

Class

hIgG2

Reactivity

Binds to human cardiac troponin I. Lack of cross-reactivity to skeletal troponin I was confirmed with ELISA using native human skeletal muscle troponin I.

Dissociation constant (K_D)

1.60 x 10^-10 M (Troponin complex binding from solution)

1 x 10^-12 M (Troponin complex binding from streptavidin surface)

Application

ELISA, CLIA, WB

Protocol

Purification

Protein A affinity chromatography followed by gel filtration.

Purity

>95%

Concentration

5 mg/ml

Buffer

50 mM Na-citrate, pH 6.0, 0.9 % NaCI, 0.095 % NaN3 (SPTN)

Related Products

Cardiac troponin I antibody clone 5F8 has been identified as a recommended capture antibody with clone 10C12 (cat# R1-135-100), clone 10G1 (cat# R1-130-100), and clone 26B5 (cat# R1-193-100). The antibody pair 5F8-10C12 was additionally validated using serum samples collected from myocardial infarction (MI) patients.

Shipping

Shipped on dry ice.

Storage

Store in -65...-85 °C. Avoid multiple freeze-thaw cycles.

Background

Cardiac troponin I (cTnI), a 24 kDa protein, is a vital part of the troponin complex, working alongside troponin T and troponin C to control the contraction and relaxation of cardiac muscle fibres. In cases of cardiac injury or stress, such as myocardial infarction (MI), the integrity of cardiac muscle cells is compromised, leading to the release of cTnI into the bloodstream. Cardiac troponin I (cTnI) possesses a remarkable specificity for the heart muscle, rendering it an invaluable diagnostic tool in identifying myocardial infarction (MI). Consequently, cTnI has attained the status of the gold standard biomarker for diagnosing myocardial injury, with a particular emphasis on myocardial infarction. Given that the majority, if not all, of the cTnI molecules in the blood exist as binary (cTnI-C) or ternary complexes (cTnT-I-C), it's crucial to utilize cTnI-specific antibodies that can precisely recognize the troponin complex when designing an assay.